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Abstract We have previously shown that the carboxyl-terminal 
region of human immunodeficiency virus type 1 (HIV-1) Nef 
antigen present on the outer surface of virus-infected cells has 
affinity for uninfected T cells. Here, the in vitro cytotoxic 
potential of HIV-1 Nef on the T cell surface against CD4+ T 
cells was investigated in detail. Human T cells expressing Nef on 
the cell surface by transfection with non-infectious mutant HIV-1 
proviruses were demonstrated to kill CD4+ T cells effeciently. 
Furthermore, it was shown that the carboxyl-terminal portion of 
Nef was cytotoxic for CD4+ T cells and that monoclonal 
antibody against the carboxyl-terminal region of Nef inhibited 
Nef induced-cytolysis. Thus, we concluded that Nef protein on 
CD4+ T cells may play an important role in the specific loss of 
CD4+ T lymphocytes during HIV-1 infection. 
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1. Introduction 
The human immunodeficiency virus type 1 (HIV-1) is a 
complex retrovirus that contains several auxiliary (nef, vif, 
vpr, and vpu) [1,2] and two regulatory (tat and rev) genes in 
addition to the structural genes common to all retroviruses 
(gag, pol, and env) [3-8]. Nef  is encoded by an open reading 
frame located at the 3' end of  the viral genome, partially 
overlapping the 3' long terminal repeat (LTR). Conservation 
of this coding region among all strains of HIV-1, HIV-2 as 
well as simian immunodeficiency viruses (SIV) suggests that 
Nef  plays an important role in natural infection. The role of 
HIV-I  Nef  in the virus life cycle in vitro has been controver- 
sial. Earlier reports described that Nef  reduces the rate of 
HIV-1 replication and represses the HIV-I  LTR promoter 
activity [9-11]. However, these results were not confirmed 
by other investigators [12-14]. Recent studies demonstrated 
that Nef  has a positive effect upon HIV-1 replication in T 
cells and acts at a very early stage of the replication cycle 
[14-18]. Consistent with this Nef-enhanced virion infectivity 
in vitro, Nef has been shown to be essential for efficient viral 
replication in SCID-Hu mice in vivo [19]. Furthermore, Nef  
from a macaque strain of SIV, SIVmac239, is required for 
efficient virus replication and for induction of immunosup- 
pressive disorders in rhesus monkeys [20]. Apart from its func- 
tional role in virus replication, several biologically important 
activities of HIV-1 Nef, such as the down-modulation of CD4 
expression, have been documented [21]. 
In this study, we demonstrated that the carboxyl-terminal 
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domain of HIV-1 Nef  on the cell surface specifically induces 
cytolysis of the CD4+ T cells. 
2. Materials and methods 
2.1. Cells 
Human CD4+ T cell lines, Molt4 and Molt4 clone 8, were main- 
tained in RPMI-1640 medium supplemented with 10% heat-inacti- 
vated fetal bovine serum (FBS) and 100 gg/ml of streptomycin and 
100 IU/ml of penicillin. 
2.2. Antibodies 
Three murine monoclonal antibodies (mAb) to Nef, designated F1, 
E7, and E9, were used and the epitopes recognized by F1, E7, and E9 
covered the amino acid sequences 148-157, 192-206, and 158-206 of 
Nef [22]. The mAbs to HIV-1 Env gpl20 and Gag p24 were purchased 
from Repligen and Cellular Products Inc. The OKT4 conjugated with 
FITC, and OKT8 conjugated with PE were purchased from Ortho 
Diagnostic System. 
2.3. Plasmid construction and protein expression 
The mutant plasmid DNAs of HIV-1, designated pNL-Ac, pNL- 
Psi, pNL-Ps2, pNL-B1, pNL-Afl, pNL-ABM, pNL-Kp, pNL-St, 
pNL-Hi, and pNL-Xh have been previously described [23]. Plasmids, 
pLRNL (MuLV-based plasmid), pL001+ and pL001- also have 
been described previously [24]. The BamHI fragments of sCD4 in 
pUC119 were cut with RsaI, and the Xhol-HindlII fragments of nef 
in pCV-1 were inserted into the digested plasmid (pUCs-nef). Plasmid 
pL101 was constructed by ligating the BamHI fragments of pUCs-nef 
plasmid into BamHI site of pLRNL plasmid. Plasmid pL212, pL334, 
and pL453 were constructed by cutting at the XhoI-BgllI (at nucleo- 
tide 8627), -EcoRV (at nucleotide 8694) and -EcoRV (at nucleotide 
8773) sites of pL101 plasmid, end filling with the Klenow polymerase, 
and religation. The pL598 plasmid was constructed by cutting pL101 
at EcoRV~PVUII sites, end filling with the Klenow polymerase, and 
then religation to generate a new stop codon 301 bp downstream of 
the XhoI site of the nef fragment (Fig. 4). 
Molt4 cells (5 × 106) were transfected with HIV-I mutant DNA or 
MuLV-based plasmid DNA (10 gg) mixed with 5 gl of lipofectin [25] 
and were cultured for 30 h at 37°C in 0.5 ml of RPMI-1640 medium 
containing 10% Nuserum IV (Becton Dickinson) in a 24-well culture 
dish. After the culture, 1 ml of FBS was overlaid with 0.5 ml of the 
harvested cell suspension and cells were centrifuged at 200×g for 10 
min. The supernatant containing dead cells was removed. The cells 
were washed 3 times and were used for cytotoxic assay. 
2.4. Flow cytometry 
Flow cytometry was performed essentially as described previously 
[221. 
2.5. Cytotoxic assay 
Cytolytic death of T cells was determined by the method of Slezak 
and Horan [26]. Cell surface of Molt4 clone 8 cells (1-8X l06) was 
labeled with a fluorechrome, PKH-26 (Zynaxis Cell Science Inc.). 
Effector cells (1 × 106) expressing recombinant HIV-1 proteins were 
prepared as described above. For assay of cytotoxicity inhibiting ac- 
tivity of mAbs to Nef, 2-fold dilutions of the mAbs were added to 
both cell mixture during the co-culture. The cells harvested were 
stained with 1× l0 -6 M propidium iodide (PI) and analyzed by 
flow cytometry. The effector cells were gated out by FS and SS, 
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and incorporation ofPI into PKH-26-1abeled target cells was analyzed 
with use of two colored histograms. Filters used to select for different 
parameters were: PKH-26, 525 band pass filter; PI, 590 long-pass 
glass filter. The percentage cytotoxicity was calculated by the equa- 
tion: 
%lysis = (quadrant [Q]2/Q2 + Q4 specific - Q2/Q2 
+ Q4 spontaneous) × 100. 
The Q4 presented ascells which are positive only for PKH-26 fluore- 
sence and the Q2 contained ead target cells which are positive for 
PKH-26 and PI staining. The values of Q2 and Q4 'specific' were 
determined by the number of events in each sample. The Q2 and 
Q4 'spontaneous' were determined by the number of events in a con- 
trol sample containing only target cells. 
3. Results 
3.1. Cytotoxicity of human T cells transfected with 
non-infectious HIV-1 mutants aga&st CD4+ T cells 
We examined whether human T cells expressing HIV-1 Nef 
on the cell surface kill CD4+ T cells. Non-infectious HIV-1 
mutants with intact nef and various defects in the other genes 
(Fig. 1) were transfected into Molt4 cells as effector cells. 
Effector cells that were transfected with gag mutants (pNL- 
Ac and pNL-Psl), pol mutants (pNL-Ps2, pNL-B1 and pNL- 
Afl), or env mutants (pNL-Kp, pNL-St and pNL-Hi) effec- 
tively killed CD4+ target cells within 8 h (Fig. 2). In contrast, 
effector cells transfected with tat mutant pNL-ABM did not 
show significant cytotoxicity to the target cells. In addition, 
cells transfected with the infectious mutant pNL-Xh carrying 
the inactive nefgene did not kill Molt4 clone 8 cells within 8 h. 
After 12 h of co-culture, however, 24.9 +0.5% of target cells 
died probably by the effect of Env. 
To investigate whether the fluctuation of cytotoxic effi- 
ciency among the effector cells was due to the difference in 
the amount of Nef expressed on the cell surface, we examined 
the level of the effector cells for cell surface Nef by membrane 
immunofluorescence at the same time of cytotoxic assay (Fig. 
3). Cell surfaces of Molt4 cells transfected with pNL-Ac, -Ps 1, 
-Ps2, -B1, -Afl, -Kp, -St, or -Hi were similarly stained with E7, 
strongly with E9, faintly with F1, and not at all with IgM 
control. The surface of cells transfected with pNL-Ac, 
-Psi, -Ps2, -B1 or -Afl were also stained with anti-Env 
mAb. Cells transfected with pNL-Ps2, pNL-B1 or pNL-Afl 
produced Gag p24 protein that was observed by immunoblot- 
ting with anti-Gag p24 mAb (data not shown). However, 
when transfected with pNL-ABM, the cell surface was not 
stained with any of the mAbs and Gag p24 was not observed 
at all in the cells. None of pNL-Kp, -St or -Hi-transfected 
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Fig. 1. Schematic representation f HIV-1 mutants used in this 
study. The sites of mutation within proviral genome of HIV-1 are 
indicated by arrows. Designations of the mutants are shown at the 
bottom, pro, protease; RT, reverse transcriptase; end, endonuclease. 
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Fig. 2. Cytotoxic activity of Molt4 cells transfected with HIV-I mu- 
tants against Molt4 clone 8 cells. Molt4 cells were transfected with 
HIV-1 mutants, and after 30 h, cytotoxicity was determined at 8 h 
post-co-culture at the effector to target Molt4 clone 8 cell ratio of 
1:1 (n) and 5:1 (m). Percent lysis was determined by flow cyto- 
metric analysis. Data are expressed as the mean + SE of three sepa- 
rate experiments. 
cells were stained with anti-Env mAb but Gag p24 was found 
in the cells. These results howed that cell surface expression 
of the carboxyl-terminal domain of Nef, recognized by E7 and 
E9, was responsible for cytotoxicity to CD4+ T cells. 
3.2. Cytotoxicity of carboxyl-terminal region of HIV-1 Nef to 
CD4+ cells 
Plasmids, which can express full-length Nef or truncated 
Nef, were constructed (Fig. 4) and the surface expression of 
the full-length and truncated Nef forms in Molt4 cells was 
examined by flow cytometry with anti-Nef mAbs (Fig. 5). 
When pL001 + expressing full-length Nef (amino acid residues 
1-206) and pL598 (aa 34-136) with a deletion in the carboxyl- 
terminal region were examined, transfected cells did not react 
with any anti-Nef mAbs. We previously observed that, with- 
out co-expression of Gag or Env, the full-length Nef was not 
expressed on the surface of cells (manuscript submitted). On 
the contrary, cells transfected with pL101 (aa 34-206), 212 (aa 
84-206), 334 (aa 108-206), or 453 (aa 136-206), all of which 
can express ignal peptide, were found to react with E7 and 
E9 strongly. F1 mAb stained the surface of cells transfected 
with pL101, 212, or 334, but did not react to cells transfected 
with pL453. These results, therefore, indicate that the carbox- 
yl-terminus of Nef was expressed on Molt4 cells transfected 
with pL101, 212, 334 or 453. 
Next, the carboxyl-terminus of Nef expressed on T cells was 
examined for cytotoxic effects against Molt4 clone 8 cells. As 
presented in Fig. 6, Molt4 clone 8 cells were effectively lysed 
by effector cells transfected with pL101, 212, 334, or 453. On 
the other hand, significant cell killing was not observed using 
effector T cells transfected with pLRNL, 001-, 001+, or 598. 
Anti-Nef mAb E7, which recognizes the carboxyl-terminal 
region of Nef, inhibited the cytotoxic activity of cells trans- 
fected with pL101 but control normal mouse IgM did not. 
These data also suggest hat the C-terminus of Nef protein, 
especially amono acid residues 136-206, is important for 
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Fig. 3. Surface xpression of Nef protein on CD4+ T cells. HIV-1 mutants were transfected into Molt4 cells and surface levels of Env, Gag, 
and Nef antigen were determined 30 h later by flow cytometric analysis. Cells were stained with anti-gpl20 Env mAb, anti-p24 Gag mAb, anti- 
Nef mAbs (E7, E9, and F1), and normal mouse IgM. Antigenic epitopes recognized by each anti-Nef mAb were described in Section 2. 
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Fig. 4. Structures of MuLV-based plasmids encoding full-length 
myristoylated Nef (pL001) and signal peptides-fused, truncated ver- 
sion of Nef (pL101, 212, 334, 453, 598). Nef expressing plasmids 
were constructed as described in Section 2. The numbers on the top 
indicate the amino acid residues of Nef. 
CD4+ T cell killing. The cell death observed here was apop- 
tosis as judged by morphology (data not shown). 
4. D iscuss ion  
Our present study showed that human T cells expressing 
Nef on the surface specifically caused cytolysis of the uni- 
fected cells (Figs. 2 and 6). We further examined the cytolytic 
activity of Nef using various cells. While CD4+ T cells pre- 
pared from peripheral blood mononuclear cells (PBMC) were 
lysed effectively by this cell surface Nef, CD8+ T cells from 
PBMCs and some of CD4+ T cell lines were not killed (manu- 
script submitted). Inhibition of the cytotoxic activity of effec- 
tor cells by anti-Nef mAbs recognizing the carboxyl-terminal 
domain and retainment of cytotoxic activity of truncated Nef 
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Fig. 5. Cell surface xpression of truncated Nef version. Molt4 cells 
were transfected with MuLV-based plasmids (Fig. 4), cultured for 
30 h, and the expression levels of C-terminus of Nef on the cell sur- 
face were determined by flow cytometric analysis using anti-Nef 
mAbs (E7, E9, and FI), and normal mouse IgM. 
lacking amino-terminal region clearly show an important role 
of the carboxyl terminus of Nef for the cytotoxicity against 
CD4+ T cells. Soluble Nef, which lacks amino-terminal do- 
main, did bind to uninfected CD4+ T cells and induced cell 
lysis upon cross-linking by anti-Nef antibodies (our unpub- 
lished results). It seems likely that the carboxyl-terminal struc- 
ture (aa 136-206) of Nef is solely responsible for the cytotoxi- 
city and Nef binding protein may present on certain 
population of CD4+ T cells. It has been shown that among 
HIV-1 strains isolated from long-term survivors of HIV-l-in- 
fected individuals, two stretches in the Nef are variable, one of 
which is located between amino acids 189 and 200 [27]. Dea- 
con and his colleages [28] have reported that HIV-1 nef gene 
deletions from long-term survivors are concentrated on 3' 
LTR U3 region corresponding to the carboxyl-terminal region 
of Nef. Since this position is overlapping the putative cyto- 
toxic domain of Nef, mutations or truncations in this region 
might weaken the cytotoxic potential of Nef for uninfected 
CD4+ T cells. 
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Fig. 6. Cytotoxicity of T cells expressing wild-type and signal se- 
quence-beating version of Nef. Molt4 T cells were transfected with 
wild-type or signal peptide-bearing Nef expression plasmids. Viable 
cells were adjusted at the beginning of cytotoxic assay, and trans- 
fected cells were co-cultured with Molt4 clone 8 target cells for 8 h 
at the effector to target ratio of 1:1 (t3) and 5:1 (B). Cytolysis was 
determined by flow cytometric analysis. For inhibition of cytotoxic 
activity, anti-Nef mAb E7 (10 lag/ml) was mixed with the co-culture 
just before the start of assay. Normal mouse control IgM (100 ktg/ 
ml) was used as negative control. 
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